2023 FEBRUARY
Transporter function
Clin Pharmacol Ther. 2023;In press. Effect of hepatic impairment on OATP1B activity: Quantitative pharmacokinetic analysis of endogenous biomarker and substrate drugs
JCI Insight. 2023;8:e160437. The kidney drug transporter OAT1 regulates gut microbiome-dependent host metabolism. Granados JC, Ermakov V, Maity K, Vera DR, Chang G, Nigam SK. PubMed
Clin Pharmacol Ther. 2023;In press. Association between ABCG2, ABCB1, ABCC2 efflux transporter single-nucleotide variants and Irinotecan adverse effects in patients with colorectal cancer: A real-life study. Barnett-Griness O, Rennert G, Lejbkowicz F, Pinchev M, Saliba W, Gronich N. PubMed
Eur J Pharm Sci. 2022;181:106362. Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs. Deng F, Sjöstedt N, Santo M, Neuvonen M, Niemi M, Kidron H. PubMed
Front Pharmacol. 2023;13:1085621. Investigating bile acid-mediated cholestatic drug-induced liver injury using a mechanistic model of multidrug resistance protein 3 (MDR3) inhibition. Beaudoin JJ, Yang K, Adiwidjaja J, Taneja G, Watkins PB, Siler SQ, Howell BA, Woodhead JL. PubMed
Experimental models
Res Sq. 2023;In press. HepaRG cells undergo increased levels of post-differentiation patterning in physiologic conditions when maintained as 3D cultures in paper-based scaffolds. Diprospero TJ, Brown LG, Fachko TD, Lockett MR. PubMed
Pharmaceutics. 2022;15:29. Role of hepatocyte transporters in Drug-Induced Liver Injury (DILI)-In vitro testing. Tátrai P, Erdő F, Krajcsi P. PubMed
Molecules. 2023;28:621. Drug metabolism of hepatocyte-like organoids and their applicability in in vitro toxicity testing. Bouwmeester MC, Tao Y, Proença S, van Steenbeek FG, Samsom RA, Nijmeijer SM, Sinnige T, van der Laan LJW, Legler J, Schneeberger K, Kramer NI, Spee B. PubMed
Nanomedicine. 2023;48:102651. Evaluation of drug carrier hepatotoxicity using primary cell culture models. Kibar G, Dutta S, Rege K, Usta OB. PubMed
Int J Mol Sci. 2022;23:14880. Effects of pro-inflammatory cytokines on hepatic metabolism in primary human hepatocytes. Gramignoli R, Ranade AR, Venkataramanan R, Strom SC. PubMed
Reviews
Hepatology. 2023 ;In press. Mechanisms of drug resistance in hepatocellular carcinoma. Ladd AD, Duarte S, Sahin I, Zarrinpar A. PubMed
Int J Mol Sci. 2022;23:13967. The Farnesoid X receptor as a master regulator of hepatotoxicity. Rausch M, Samodelov SL, Visentin M, Kullak-Ublick GA. PubMed
Transporters and sex
Nat Commun. 2023;14:175. Deciphering genetic causes for sex differences in human health through drug metabolism and transporter genes. Huang Y, Shan Y, Zhang W, Lee AM, Li F, Stranger BE, Huang RS. PubMed
Clearance models
Drug Metab Dispos. 2023 ;In press. Process and system clearances in pharmacokinetic models: Our basic clearance concepts are correct. Korzekwa K, Nagar S. PubMed
Transporters and NASH
Nutrients. 2023;15:558. Relative enhancement in Gadoxetate Disodium-enhanced liver MRI as an imaging biomarker in the diagnosis of Non-Alcoholic Fatty Liver Disease in pediatric obesity. Hojreh A, Lischka J, Tamandl D, Ramazanova D, Mulabdic A, Greber-Platzer S, Ba-Ssalamah A. PubMed
Clin Pharmacol Ther. 2023;113:275-297. Considerations for physiologically based modeling in liver disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH). Murphy WA, Adiwidjaja J, Sjöstedt N, Yang K, Beaudoin JJ, Spires J, Siler SQ, Neuhoff S, Brouwer KLR. PubMed
Front Endocrinol (Lausanne). 2023;13:1034494. Transcriptomic profiling of hepatic tissues for drug metabolism genes in nonalcoholic fatty liver disease: A study of human and animals. Chen L, Chen L, Li X, Qin L, Zhu Y, Zhang Q, Tan D, He Y, Wang YH. PubMed